“DelveInsight’s Peripheral Neuropathic Pain Pipeline Insights 2022 report provides comprehensive insights about 10+ companies and 10+ drugs in the Peripheral Neuropathic Pain Pipeline Landscape”
DelveInsight’s, “Peripheral Neuropathic Pain Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Peripheral Neuropathic Pain pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key takeaways from the Peripheral Neuropathic Pain Pipeline Report
Download a PDF Sample Copy of the Peripheral Neuropathic Pain Clinical Trials Report, visit here- https://www.delveinsight.com/sample-request/peripheral-neuropathic-pain-pipeline-insight
Peripheral Neuropathic Pain Overview
Neuropathic pain is defined by the International Association for the Study of Pain as pain caused by a lesion or disease of the somatosensory nervous system. Neuropathic pain (NP) is not a particular disease, but the clinical condition that is caused by a variety of different diseases and lesions, injuring the nervous system at peripheral or central level, resulting in peripheral NP or central NP, respectively. The nerve damage and subsequent functional and structural neuroplasticity in sensory and autonomic nervous system, may become pathological and maladaptive in certain percentage of patients, and the risk of maladaptation depends on biological, genetic, demographic, and psychosocial factors. The nerve damage induces extensive response in immune system as well, resulting in close interactions between nervous and immune system, and finally neuroinflammation. Neuropathic pain (NP) can result from injury to either the central or peripheral nervous system.
Peripheral Neuropathic Pain Pipeline Report
Peripheral Neuropathic Pain Pipeline Insight, 2022″ report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Peripheral Neuropathic Pain pipeline landscape is provided which includes the disease overview and Peripheral Neuropathic Pain treatment guidelines. The assessment part of the report embraces, in depth Peripheral Neuropathic Pain commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Peripheral Neuropathic Pain collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Peripheral Neuropathic Pain Emerging Drugs
HSK 16149: Haisco Pharmaceutical Group
HSK16149 is a potent ligand of VGCC α 2 δ subunit with a better therapeutic index. Hence, it could be an effective and safe drug candidate for treating chronic pain. In a study, HSK16149 was found to be a novel ligand of voltage-gated calcium channel (VGCC) α 2 δ subunit. HSK16149 inhibited gabapentin binding to the α 2 δ subunit and was 23 times more potent than pregabalin. In two rat models of neuropathic pain, the minimum effective dose (MED) of HSK16149 was 10 mg/kg, and the efficacy was similar to that of 30 mg/kg pregabalin. Moreover, the efficacy of HSK16149 could persist up to 24 hours post administration at 30 mg/kg, whereas the efficacy of pregabalin lasted only for 12 hours at 30 mg/kg in streptozotocin-induced diabetic neuropathy model, indicating that HSK16149 might be a longer-acting drug candidate. HSK16149 could also inhibit mechanical allodynia in intermittent cold stress model and decrease phase II pain behaviors in formalin-induced nociception model.
ACD 440: AlzeCure
ACD440 is a TRPV1 antagonist that originated in Big Pharma and is based on a strong scientific foundation. The discovery and insight into TRPV1, the biological system that underlies ACD440 and is central to, among other things, temperature regulation and pain, was awarded the Nobel Prize in Physiology or Medicine 2021. The compound has previously undergone Phase I clinical trials, in which both good tolerability and early positive signals of efficacy were observed. The mechanism of action of the project is via TRPV1 receptors, which have a key role in pain signaling, and ACD440 has been shown in preclinical trials to have an effect on both nociceptive and neuropathic pain. The compound has previously undergone extensive preclinical safety studies and since the compound is being developed for local use, systemic exposure can be kept very low, while the concentration of the compound locally can be kept high for maximum analgesic effect.
Get to know more information of Peripheral Neuropathic Pain Emerging Therapies and Companies- https://www.delveinsight.com/sample-request/peripheral-neuropathic-pain-pipeline-insight
Peripheral Neuropathic Pain Pipeline Phases
DelveInsight’s report covers around 10+ products under different phases of clinical development like
Peripheral Neuropathic Pain Pipeline Analysis
The report provides insights into:-
To know more facts about the Peripheral Neuropathic Pain Pipeline Report, View Here-https://www.delveinsight.com/sample-request/peripheral-neuropathic-pain-pipeline-insight
Peripheral Neuropathic Pain Pipeline Therapeutic Analysis
There are approx. 10+ key companies which are developing the therapies for Peripheral Neuropathic Pain. The companies which have their Peripheral Neuropathic Pain drug candidates in the most advanced stage, i.e. phase II/III include, Haisco Pharmaceutical Group.
Scope of the Peripheral Neuropathic Pain Pipeline Report
Table of Content
For any query related to the Peripheral Neuropathic Pain Pipeline Report, then speak to the analyst here- https://www.delveinsight.com/sample-request/peripheral-neuropathic-pain-pipeline-insight
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/